NRIX

Nurix Therapeutics, Inc. (NRIX) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended May 31, 2026. Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degradation medicines for cancer and inflammatory diseases. The company utilizes a proprietary DEL-AI platform to develop drug candidates, including bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607. As of May 31, 2026, the company had 103,781,683 shares of common stock outstanding.

Key Financial Metrics

Note: Revenue is derived entirely from collaboration and license agreements; the company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $35.0 million (79%) for the three months ended May 31, 2026, compared to the same period in 2025. This was primarily due to the absence of $30.0 million in license revenue recognized in the prior year from Sanofi license extensions and a decrease in collaboration revenue from Gilead and Sanofi as initial research terms concluded.
• Increased Expenses: Research and development (R&D) expenses increased by $9.6 million (12%) for the quarter and $24.0 million (16%) for the six-month period compared to the prior year. This increase was driven by accelerated patient enrollment in bexobrutideg clinical trials, increased contract research costs, and higher personnel-related costs including stock-based compensation.
• Liquidity Position: Cash, cash equivalents, and marketable securities decreased from $688.1 million (total assets) at November 30, 2025, to $535.5 million at May 31, 2026, reflecting significant operating cash burn.

Guidance, Outlook, and Material Events

• Roche Collaboration (Subsequent Event): On June 6, 2026, the company entered into a global collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. for bexobrutideg (NX-5948). The deal includes an upfront payment of $700 million and potential milestone payments of up to $2.3 billion. The agreement is expected to become effective in the third fiscal quarter of 2026 pending regulatory approvals.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($443.5 million) are sufficient to fund operations for at least the next 12 months. The anticipated $700 million upfront payment from Roche will significantly extend the company's runway.
• Clinical Progress:
  • Bexobrutideg: A Phase 2 study in relapsed/refractory CLL commenced in October 2025. The company holds Fast Track designations from the FDA for CLL/SLL and Waldenström's macroglobulinemia.
  • Zelebrudomide: Phase 1a/1b dose escalation is ongoing following the resolution of a partial clinical hold in August 2024.
  • NX-1607: Phase 1a/1b dose escalation is ongoing for immuno-oncology indications.
• Risks: The company faces standard biotech risks including clinical trial failure, regulatory delays, and the need for additional capital. Specific risks include the uncertainty of the Roche deal closing and potential supply chain disruptions from third-party manufacturers.

Investor Verification Checklist

• Roche Deal Closing: Verify the status of the Hart-Scott-Rodino (HSR) antitrust waiting period and other regulatory clearances required for the $700 million upfront payment to be received.
• Cash Burn Rate: Monitor the quarterly net cash used in operating activities to ensure the $443.5 million cash balance remains sufficient until the Roche payment is realized.
• Clinical Trial Enrollment: Confirm patient enrollment rates for the pivotal Phase 2 bexobrutideg trial, as delays could impact future milestone payments and commercialization timelines.
• Collaboration Revenue Recognition: Review the cost-based input method used for recognizing revenue from Gilead, Sanofi, and Pfizer agreements to understand the volatility in quarterly revenue figures.
• Stock-Based Compensation: Assess the impact of the $20.8 million stock-based compensation expense (six months ended May 31, 2026) on future dilution and cash flow projections.